List of Excipients in Branded Drug GLEOLAN

« Back to Dashboard

Gleolan Excipient Strategy and Commercial Opportunities

Last updated: October 15, 2026

Gleolan is an oral powder for solution containing aminolevulinic acid hydrochloride, or 5-ALA HCl, for intraoperative fluorescence visualization of malignant glioma tissue. Its commercial position is unusual: the marketed product uses a simple, essentially excipient-free presentation, while the largest opportunities are likely to come from administration convenience, stability, supply-chain efficiency, and hospital workflow rather than conventional formulation differentiation.

The core commercial constraint is that Gleolan is an orphan, procedure-linked product used in neurosurgical centers. The addressable market is narrower than the broader oncology-drug market, but the product can support premium pricing because it is integrated into fluorescence-guided surgery and affects operating-room workflow.

What is Gleolan and how is it administered?

Gleolan contains aminolevulinic acid hydrochloride, the hydrochloride salt of 5-aminolevulinic acid. The FDA-approved product is supplied as a powder for oral solution in a single-dose vial.

Product attribute	Gleolan
Active ingredient	Aminolevulinic acid hydrochloride
Dosage form	Powder for oral solution
Route	Oral
Dose	20 mg/kg
Administration timing	Approximately 3 hours before anesthesia
Indication	Intraoperative fluorescence visualization of malignant glioma tissue
Patient setting	Hospital or specialized neurosurgical center
Regulatory pathway	FDA-approved prescription drug
FDA approval	2017
Exclusivity	Orphan-drug exclusivity applied at approval
Key technology	Protoporphyrin IX fluorescence after 5-ALA administration

After oral administration, 5-ALA is metabolized intracellularly to protoporphyrin IX. Accumulation in glioma tissue can produce visible fluorescence under appropriate surgical illumination. The product is therefore used as an adjunct to surgical visualization, not as a standalone antineoplastic therapy.[1]

The approved label requires preparation shortly before dosing. The dose is calculated by patient body weight, and the powder is reconstituted with water before oral administration. This makes dose preparation, powder handling, dissolution, taste, and timing relevant commercial issues.

What excipients does Gleolan contain?

Gleolan’s principal formulation advantage is the absence of a conventional excipient burden. The FDA prescribing information identifies the product as aminolevulinic acid hydrochloride powder for oral solution and directs reconstitution with water. The formulation is not positioned as a flavored liquid, extended-release product, tablet, capsule, or sterile injectable.[1]

That design has several consequences:

1. It minimizes excipient-related safety issues.
2. It reduces the number of formulation variables affecting fluorescence-generating activity.
3. It simplifies regulatory characterization.
4. It places more pressure on packaging, moisture control, dissolution behavior, and administration workflow.
5. It leaves room for competitors to differentiate through presentation rather than active pharmaceutical ingredient.

The relevant excipient strategy is therefore not to add ingredients indiscriminately. Any excipient must be assessed against 5-ALA HCl’s water solubility, chemical stability, taste, photoreactivity, dose flexibility, and conversion to protoporphyrin IX.

Which excipient functions are commercially relevant?

Formulation objective	Potential excipient approach	Commercial value	Main development risk
Taste masking	Sweeteners, flavors, pH modifiers, ion-exchange systems	Moderate	Added formulation complexity and pediatric-style excipient concerns
Faster dissolution	Wetting agents or optimized particle engineering	Moderate	Potential impact on stability and dose uniformity
Moisture protection	Desiccants, high-barrier blister or vial systems	High	Packaging rather than conventional excipient differentiation
Chemical stabilization	Buffer systems or solid-state stabilizers	High if required	Possible effect on degradation and bioavailability
Reduced light exposure	Opaque container, secondary carton, light-protective closure	High	Increased packaging cost
Ready-to-administer dosing	Premeasured sachets or oral liquid	High	Shortened shelf life and microbial-control requirements
Dose flexibility	Unit-dose presentations at multiple strengths	Moderate to high	Inventory complexity
Administration acceptability	Flavoring and palatability systems	Moderate	Clinical workflow and excipient tolerability

What formulation patents could protect a competing Gleolan product?

Potentially valuable intellectual-property claims would focus on the formulation and presentation rather than the active ingredient itself. The most defensible claim categories would include:

Stabilized 5-ALA compositions

Claims could cover a defined pH range, moisture content, impurity profile, solid-state form, or combination of stabilizing excipients. The commercial objective would be longer shelf life or improved tolerance to temperature excursions.

Taste-masked oral solutions

A liquid or reconstituted formulation with a defined flavoring system, sweetener, buffering system, or complexing agent could support a formulation patent. The claim must show that the excipient system improves palatability without materially changing exposure or protoporphyrin IX formation.

Unit-dose packaging

A patent could cover premeasured oral doses, moisture-resistant containers, dual-compartment packaging, or a kit combining powder and a measured volume of diluent. Packaging claims are more valuable when they solve a documented hospital-use problem.

Rapid-dissolution compositions

Particle-size control, granulation, amorphous material, or a specific excipient combination could support claims directed to dissolution time and dose uniformity. Such claims would be commercially relevant if existing preparation requirements create delays before anesthesia.

Kits for fluorescence-guided surgery

A kit could combine the 5-ALA dose, dosing cup, diluent, administration instructions, and light-protection components. Kit claims may provide a secondary barrier, although their enforceability depends on claim drafting and actual product configuration.

The strongest formulation patent would link a measurable pharmaceutical advantage to the excipient system. A claim directed only to adding a common sweetener or flavor may face obviousness challenges.

When did Gleolan lose market exclusivity?

Gleolan received FDA approval on June 6, 2017. As an orphan drug, it received seven years of orphan-drug exclusivity for the approved indication, subject to the statutory framework under the Orphan Drug Act.[2] The exclusivity period generally ran until June 6, 2024.

Orphan exclusivity prevents FDA approval of the same drug for the same orphan indication during the exclusivity period, unless the sponsor cannot provide sufficient quantities or the subsequent product is clinically superior. It is separate from patent protection and does not automatically prevent all competing products.

Gleolan also had five-year new chemical entity exclusivity associated with FDA approval, subject to statutory limitations. That period would have expired before the orphan period. The practical consequence is that the principal post-2024 barrier is likely to be formulation, manufacturing, regulatory, and commercial execution rather than unexpired regulatory exclusivity.

What is the Orange Book status of Gleolan?

Gleolan is an FDA-approved small-molecule drug and is potentially eligible for Orange Book listing. The relevant commercial questions are whether the reference product has listed patents, whether those patents remain unexpired, and whether an abbreviated new drug application can rely on the reference product’s safety and efficacy data.

For an ANDA applicant, the central patent issues would be:

• Paragraph I certification if no patent is listed.
• Paragraph II certification if a listed patent has expired.
• Paragraph III certification if the applicant will wait until patent expiration.
• Paragraph IV certification if the applicant asserts that a listed patent is invalid, unenforceable, or not infringed.

A Paragraph IV filing could trigger patent litigation under Hatch-Waxman. If the reference sponsor files suit within the statutory period, FDA approval may be subject to a 30-month stay, subject to statutory exceptions and court developments.[3]

The commercial importance of Orange Book patents depends on whether they cover the active ingredient, formulation, method of use, or only a narrow presentation. A weak or expired formulation patent would offer limited protection against an ANDA product using a different excipient system.

What generic entry risks exist for Gleolan?

The regulatory pathway depends on the proposed product.

ANDA pathway

An ANDA applicant could seek approval for a product pharmaceutically equivalent to Gleolan. The applicant would need to address:

• Same active ingredient and strength.
• Same dosage form and route.
• Pharmaceutical equivalence.
• Bioequivalence or an accepted waiver strategy.
• Labeling requirements.
• Manufacturing and stability data.
• Handling and light-protection requirements.

Because Gleolan is a powder for oral solution, the product may offer a relatively straightforward equivalence framework compared with modified-release or complex injectable products. A competitor could avoid formulation patents by using different excipients, packaging, or flavoring while maintaining the same active ingredient and dose.

505(b)(2) pathway

A 505(b)(2) application could support a product with a different formulation, presentation, or administration system. Examples include:

• A flavored oral solution.
• A ready-to-use liquid.
• A premeasured dose kit.
• A different concentration.
• A formulation with improved stability.
• A product paired with a validated dosing device.

A 505(b)(2) product could obtain its own labeling or exclusivity for a clinically meaningful modification, but it would face additional bridging and clinical-development requirements.

Generic substitution

Automatic substitution depends on FDA rating and product equivalence. A clinically useful but formulation-different 505(b)(2) product may not receive the same substitution treatment as an AB-rated ANDA product. That distinction affects hospital contracting and launch economics.

What excipient strategies offer the strongest commercial opportunity?

1. Ready-to-use oral liquid

A ready-to-use liquid could remove reconstitution steps and reduce preparation errors. Its main challenges would be chemical stability, microbial control, container compatibility, light sensitivity, and shipping weight.

A commercially viable liquid would need a shelf life comparable to the current powder product or a clear operating-room benefit that justifies shorter dating and higher logistics costs.

2. Palatable reconstituted solution

A taste-masked product could improve administration for patients who experience nausea or difficulty ingesting the solution. The opportunity is more compelling if the product can preserve the current dosing schedule and avoid additional pharmacy compounding.

Candidate approaches include low-level sweeteners, flavor systems, buffering agents, and taste-masking combinations. The formulation must avoid materially changing absorption or the timing of protoporphyrin IX generation.

3. Premeasured weight-band doses

Gleolan is dosed by body weight. Unit doses aligned to weight bands could reduce calculation and preparation time. A weight-band system could be sold as a hospital kit with clearly labeled dose units.

The main tradeoff is inventory. Hospitals would need multiple presentations, and waste could rise when patient weight falls between available units.

4. Moisture- and light-protective packaging

This is likely the lowest regulatory-risk opportunity. A high-barrier vial, sachet, blister, or dual-pack system could improve stability without materially changing the formulation.

Packaging improvements could also support decentralized storage in operating-room pharmacies, reduce preparation losses, and simplify compliance with handling instructions.

5. Integrated dosing kit

A kit containing the drug, diluent, dosing vessel, and instructions could create workflow value. The kit could be designed for pharmacy preparation several hours before surgery and standardized across hospitals.

The IP position would likely depend on the combination of components and the operational method. The kit would need to avoid unnecessary accessories that increase cost without reducing preparation time.

How strong is the Gleolan patent estate?

The active ingredient, 5-ALA, is an established chemical entity with prior medical and diagnostic uses. That limits the prospect of broad composition-of-matter protection for the active ingredient itself. The strongest remaining protection, if available, would more likely involve:

• The approved fluorescence-guided glioma use.
• Specific dosing and timing.
• Formulation stability.
• Solid-state or particle characteristics.
• Packaging and administration kits.
• Manufacturing controls that produce a defined impurity profile.

Method-of-use patents may have commercial value because the product is tied to a defined surgical procedure. Their practical enforcement value is narrower than composition patents because hospitals and surgeons may use alternative products or challenge claim scope.

The patent estate should therefore be assessed as a product-specific barrier rather than as a broad, durable platform estate. After orphan exclusivity, an entrant with a compliant powder formulation could create meaningful price pressure if no enforceable formulation or method patents remain.

Which companies could challenge Gleolan commercially?

Competitive pressure can come from three groups:

1. Generic-drug manufacturers developing an ANDA.
2. Specialty pharmaceutical companies pursuing a 505(b)(2) product.
3. Diagnostic or surgical-technology companies integrating 5-ALA with fluorescence imaging systems.

Potential competitors may seek to differentiate through price, supply reliability, taste, preparation time, packaging, or geographic distribution. The most credible entrant is likely to be a manufacturer with existing oral powder, oncology, hospital, or surgical-product capabilities.

A competitor does not need to replicate every aspect of Gleolan’s presentation. A different excipient system may be commercially acceptable if the active ingredient, dosage form, and performance meet FDA requirements.

What licensing opportunities exist for Gleolan excipient technology?

Licensing opportunities are strongest in four areas:

Technology	Likely licensee	Value proposition
Stabilized 5-ALA powder	Generic or specialty-drug company	Longer shelf life and lower shipping risk
Palatability system	505(b)(2) sponsor	Better patient acceptance
Ready-to-use liquid	Hospital-focused drug company	Lower preparation burden
Unit-dose packaging	Reference or generic manufacturer	Reduced pharmacy errors and workflow time

A technology owner should seek claims and data covering dissolution, stability, impurity formation, bioavailability, and fluorescence performance. A formulation that tastes better but changes exposure or tissue fluorescence may have limited licensing value.

What manufacturing and IP barriers affect commercial entry?

Manufacturing barriers are manageable but material. The entrant must control:

• Active-ingredient assay and impurity profile.
• Water content and moisture ingress.
• Powder flow and dose uniformity.
• Dissolution after reconstitution.
• Container-closure integrity.
• Light exposure during production and storage.
• Stability under labeled storage conditions.
• Batch-to-batch performance in a weight-based dosing product.

The product’s low excipient count does not eliminate CMC risk. It shifts risk toward active-material quality, solid-state behavior, packaging, and preparation controls.

Geographic expansion also matters. Gleolan is known as Gliolan in Europe and has been used for fluorescence-guided resection of malignant glioma under European regulatory frameworks.[4] A regional strategy must account for different regulatory classifications, patent registers, hospital procurement systems, and labeling requirements.

How does Gleolan compare with conventional oncology drugs?

Factor	Gleolan	Conventional systemic oncology drug
Primary value driver	Surgical visualization	Disease treatment
Dosing frequency	Per surgical procedure	Repeated cycles or chronic dosing
Administration	Oral preoperative dose	Oral or parenteral treatment
Excipient differentiation	High potential in taste, stability, and workflow	Often focused on delivery and tolerability
Prescriber	Neurosurgeon and hospital team	Medical oncologist or specialist
Market access	Hospital procedure budgets	Pharmacy and medical benefit
Generic substitution	Potentially sensitive to workflow and preparation	Usually driven by price and equivalence
Commercial risk	Procedure volume and center adoption	Patient population and treatment duration

Key Takeaways

• Gleolan is an oral powder for solution containing aminolevulinic acid hydrochloride for fluorescence-guided malignant glioma surgery.
• Its low-excipient formulation leaves commercial room for improved taste, dissolution, packaging, dose preparation, and ready-to-use presentations.
• Orphan-drug exclusivity from the 2017 FDA approval generally expired in June 2024.
• Generic risk is highest from an ANDA product using a different excipient and packaging system, assuming no enforceable listed patent blocks approval.
• A 505(b)(2) product could compete through a flavored liquid, premeasured dose, or integrated administration kit.
• The strongest commercial formulation opportunities are moisture-protected powder presentations, unit-dose kits, and stable ready-to-use liquids.
• The active ingredient is unlikely to support broad new composition-of-matter protection; formulation, packaging, method-of-use, and manufacturing claims are more relevant.
• Gleolan’s value is tied to neurosurgical workflow, so commercial differentiation must reduce preparation burden or improve supply reliability.

FAQs About Gleolan Excipient Strategy

Is Gleolan free of inactive ingredients?

The marketed presentation is a powder for oral solution with no prominent conventional excipient platform. Water is used for reconstitution before administration.

Can a generic Gleolan product use different excipients?

Yes. A competing product may use a different excipient system if it satisfies FDA equivalence, quality, stability, labeling, and performance requirements.

Would a flavored Gleolan product need new clinical studies?

The requirement would depend on the regulatory pathway and the extent to which flavoring changes formulation behavior, exposure, or administration. A materially different product may require a 505(b)(2) strategy rather than a conventional ANDA.

Is Gleolan a biologic with biosimilar risk?

No. Gleolan is a small-molecule drug. The relevant competitive pathways are generally ANDA and 505(b)(2), not biosimilar approval.

What is the highest-value formulation opportunity for Gleolan?

A stable, premeasured, palatable product that reduces pharmacy preparation time while preserving the existing dose and surgical timing has the strongest combination of commercial utility and regulatory feasibility.

References

1. U.S. Food and Drug Administration. (2017). Gleolan (aminolevulinic acid hydrochloride) prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Orphan drug designation and exclusivity.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations.
4. European Medicines Agency. (2017). Gliolan: EPAR product information.